Fred Alger Management LLC lowered its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 42.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,806 shares of the biotechnology company's stock after selling 47,048 shares during the period. Fred Alger Management LLC owned 0.11% of Ascendis Pharma A/S worth $10,101,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Balyasny Asset Management L.P. acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $2,123,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $28,000. Tema Etfs LLC acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $2,621,000. Soleus Capital Management L.P. acquired a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $19,824,000. Finally, Vestal Point Capital LP lifted its stake in shares of Ascendis Pharma A/S by 108.0% in the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock worth $71,588,000 after acquiring an additional 270,000 shares during the period.
Analyst Ratings Changes
A number of brokerages have recently issued reports on ASND. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a report on Tuesday, August 19th. Bank of America increased their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. UBS Group reiterated a "buy" rating and issued a $307.00 price target (up previously from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Royal Bank Of Canada raised their target price on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and an average target price of $244.36.
Check Out Our Latest Stock Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Performance
NASDAQ:ASND traded down $2.09 during mid-day trading on Friday, hitting $195.58. 227,293 shares of the company's stock traded hands, compared to its average volume of 403,501. The firm's 50 day simple moving average is $185.36 and its 200 day simple moving average is $169.72. Ascendis Pharma A/S has a 1 year low of $114.53 and a 1 year high of $208.16. The company has a market cap of $11.97 billion, a PE ratio of -37.90 and a beta of 0.39.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
See Also
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
